Skip to content
Summer 2026 · 26% off every plan with SUMMER26 See pricing
Optionomics
PRGO · 10-Q filed May 6, 2026

PRGO earnings analysis

What we found in PRGO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.

Our reading of the filing · Free to read, no account needed

Perrigo Company plc reported Q1 2026 results featuring a revenue of $969 million, missing expectations of $1.02 billion, while EPS was $0.43, beating estimates of $0.33. The overall performance challenges stem from lower consumption rates in key markets and a substantial goodwill impairment charge impacting operating income, which turned negative at $(372.3 million). Management anticipates recovery in the latter half of 2026 amidst ongoing restructuring efforts following recent divestitures.

What stood out

The parts that mattered.

Pulled out of the filing itself, with the figures the company reported.

Beat EPS Estimates
Perrigo reported an EPS of $0.43, exceeding the estimate of $0.33 by 30.3%.
Revenue Decline
Net sales fell to $969 million, down $74.7 million or 7.2% year-over-year, missing the consensus estimate of $1.02 billion.
Operating Loss Significantly Increased
Operating income plunged to $(372.3) million, a drop of $419.2 million from $46.9 million in Q1 2025, largely due to a goodwill impairment charge.
Specialty Care Segment Grows
The Specialty Care segment saw a revenue increase of $7.9 million, or 4.0%, driven by foreign currency translation and strong performance of specific brands.
Significant Cash Outflow from Operations
Operating cash flow was negative at $(113.6) million, worsening from $(64.5) million in the same quarter last year.
Goodwill Impairment Charge
The company recognized a substantial goodwill impairment charge totaling $330.8 million, heavily impacting operating margins.
What to watch

And the other side of it.

The offsets in the same document — the things a summary that only listed the good news would have left out.

Goodwill Impairment Risk
Perrigo recorded a goodwill impairment charge of $330.8 million, raising concerns over future asset valuations.
Supply Chain and Inflationary Pressures
Ongoing inflation and supply chain disruptions could adversely impact margins and sales, complicating recovery efforts.
Legal and Regulatory Risks
Potential litigation or regulatory issues, particularly in the infant formula segment, may lead to significant financial liabilities.
The numbers

What they reported.

What the company itself reported, taken out of the document.

What survived to operating profit
Of every $100 of revenue Cost of sales $66 Operating expenses $72 Left as operating profit $-38
Percentages of revenue, taken from the filing. Drawn this way because it holds whatever scale the company reports in.
Earnings per share
$0.43
Gross margin
33.6%
Operating margin
-38.4%
Segment
Self Care
Segment
Specialty Care
Segment
Infant Formula
Segment
All Other
Guidance

What they said about what is next.

Management anticipates improved performance in the second half of 2026 but did not provide specific numerical guidance.

How we read the filing overall

The filing reads worse than the one before it.

One reading of one document. It is not advice, and it is not a forecast.
Earlier filings

What came before.

10-K · February 26, 2026
Perrigo positions itself as a pure‑play self‑care company focused on store brands and a set of higher‑margin branded franchises, executing a ‘Three‑S’ plan to Stabilize, Streamline and Strengthen the business. The 10‑K…
10-Q · November 5, 2025
Perrigo reported net sales of $1,043.3 million for the three months ended September 27, 2025, down from $1,087.5 million a year ago, with gross profit of $377.1 million (gross margin ~36.1%) and operating income of…
10-Q · August 6, 2025
Perrigo reported quarterly net sales of $1,056.3 million (three months ended June 28, 2025) versus $1,065.5 million a year ago, and GAAP diluted EPS (loss) of $(0.06) versus $(0.79) in the prior-year quarter. Operating…
10-Q · May 7, 2024
Perrigo reported Q1 net sales of $1,082.1 million (down $99.6M or ~8.4% YoY from $1,181.7M) and a GAAP diluted EPS of $0.01 (net income $2.0M) versus a net loss of $(3.0)M year-ago. Gross profit fell to $357.7M (gross…

This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.

Read the next one first.

We read every filing PRGO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.

Cancel anytime · Month to month · Switch tiers whenever